Introduction {#s1}
============

Septic shock is a serious type of sepsis, mainly manifested as severe hypotension by low systolic pressure (≤90 mmHg) or mean arterial blood pressure (≤65 mmHg) accompanied by signs of hypoperfusion ([@B1]). The previous study found that septic shock is the fifth leading cause due to premature mortality ([@B2]). According to the latest guideline ([@B3]), standard rescue measures for septic shock include circulation, respiratory support, and antibiotic application. Among these, effective hemodynamic support and fluid resuscitation are the key measures for successful treatment of septic shock.

For septic shock, vasoactive drugs are important means to maintain the stability of hemodynamics and ensure the perfusion of major organs. Norepinephrine (NE) is the first-line drug for septic shock ([@B3]). However, NE mainly acts on the alpha-adrenergic receptor (alpha-receptor) of peripheral vascular resistance, which can increase cardiac after-load and thus reduce the volume responsiveness of patients. What's more, NE may induce life-threatening arrhythmia (i.e., ventricular tachycardia, ventricular fibrillation) ([@B4]). Herein, alternative, non-adrenergic vasopressors are desirable as first- or second-line treatment of sepsis-associated vasodilation, hoping that they can play a synergistic effect of NE or reduce the dosage of NE, so as to minimize the occurrence of adverse reactions.

Recently, a number of randomized controlled trials (RCTs) compared terlipressin (TP) with NE in the treatment of septic shock, but there are still some controversies in terms of mortality and adverse reactions ([@B6]; [@B5]; [@B7]). According to the pharmacological research, TP has stronger binding specificity for the V1 receptor, which made it more effective than other vasoactive drugs in sepsis-induced refractory hypotension. What's more, previous studies showed the mortality and doses of NE in patients with septic shock could be decreased by TP ([@B9]; [@B11]). While the exited two reviews had different results on vasoactive drugs for septic shock ([@B10]; [@B11]). In view of this, it is necessary to perform a meta-analysis to evaluate the efficacy and safety of TP and NE for septic shock, so as to provide evidence-based evidence for the treatment of septic shock.

Methods {#s2}
=======

This meta-analysis was conducted according to the recommendations and checklist from the preferred reporting items for systematic review and meta-analysis (PRISMA) statement ([@B12]).

Search Strategy {#s2_1}
---------------

The relevant RCTs from Medline, Cochrane Library, and Embase were searched. The duration is from their inception to March 2019. Besides, references of the selected articles were also searched as supplementary search. The search strategy of Medline was shown in [**Supplemental Figure S1**](#SM1){ref-type="supplementary-material"}.

Eligibility Criteria of Original Studies {#s2_2}
----------------------------------------

Inclusion criteria: (1) Participants: Adult participants suffered from septic shock, the diagnostic criteria should be explicit and normative, regardless of the gender and ethnicity; (2) Intervention: TP; (3) Control: NE; (4) Outcomes: Primary outcome: ICU mortality, Secondary outcomes: Adverse events (AEs), mean arterial pressure (MAP), heart rate (HR), urinary output, serum creatinine (Scr), oxygenation index (OI), total bilirubin, alanine transaminase (ALT), aspartate aminotransferase (AST). (5) Study design: RCT.

Exclusion criteria: (1) TP plus dopamine or NE as the intervention; (2) duplicate publication and the research data cannot be achieved.

Study Selection {#s2_3}
---------------

Two reviewers independently identified studies through inclusion criteria by screening the title and abstract of each record and retrieved their full text if necessary. Any disagreement between the two reviewers was solved with a discussion with a third reviewer. Otherwise, the agreement was accomplished by a consensus.

Data Extraction and Quality Assessment {#s2_4}
--------------------------------------

Two reviewers independently extracted the information from the included studies. The information includes the first author, published year, sample size, the baseline of the included studies, intervention, and endpoints. Any disagreement between the two reviewers was solved with a discussion with a third reviewer. Otherwise, the agreement was accomplished by a consensus.

A modified Jadad scale was used to assess the quality of the selected RCTs. The items of modified Jadad scale were listed in the protocol ([@B13]). According to its principle, 1--3 scores indicating a low-quality study and 4--7 scores indicating a high-quality study, the maximum of Jadad score is 7.

Data Synthesis {#s2_5}
--------------

Statistical analysis of this meta-analysis was performed by Stata software (version 11.0, Stata Corp LP, USA). Risk ratios (RRs) and 95% confidence intervals (CIs) were employed to assess the dichotomous endpoints. If the continuous variables need to be analyzed, we would choose the mean difference and its 95% CI. The heterogeneity was assessed by I^2^ test (low heterogeneity is defined as I^2^ ≤ 25%; if I^2^≥75%, it will be considered as high heterogeneity). The fixed-effect model was applied if there was no or low heterogeneity, and pooled RRs were estimated using the Mantel--Haenszel method. Publication bias was assessed if there are more than 10 studies in one outcome. All hypotheses were tested at the alpha = 0.05 level.

Subgroups Analysis {#s2_6}
------------------

Subgroups will be analyzed based on the different types of adverse events (AEs) or different time (MAP, HR, urinary output, Scr, OI, total bilirubin, ALT, AST).

Results {#s3}
=======

Description of Included Studies {#s3_1}
-------------------------------

Retrieval process of the included studies is shown in [**Figure 1**](#f1){ref-type="fig"}. Six studies ([@B5]; [@B17]; [@B18]; Liu et al., 2017; [@B16]; [@B14]) with 756 participants were included ([**Figure 1**](#f1){ref-type="fig"}). The characteristics of the six studies are listed in [**Table 1**](#T1){ref-type="table"}. The quality of the above RCTs is shown in [**Supplementary Table S1**](#SM9){ref-type="supplementary-material"}.

![Flow chart of included studies selection.](fphar-10-01492-g001){#f1}

###### 

The characteristics of the included studies.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study    No. of participants          Mean age (year)                    Intervention                               Outcomes             
  -------- ---------------------------- ---------------------------------- ------------------------------------------ -------------------- ------------------------------------------------
  [@B5]    N = 20 (T = 10;\             T: 66 (23--79) C: 65 (24--76)      Terlipressin (1 mg bolus)                  NE (0.3 ug/kg/min)   ICU mortality, Urinary output
           C = 10)                                                                                                                         

  [@B45]   N = 57 (T = 31;\             T:58.5 ± 17.8\                     Terlipressin (0.01--0.04 U/min)            NE(\> 1 ug/min)      ICU mortality, MAP, HR, OI,\
           C = 26)                      C:55.7 ± 16.1                                                                                      Urinary output, Scr

  [@B16]   N = 84 (T = 42;\             T:46.76 ± 12.11\                   Terlipressin (1.3--5.2 ug/min)             NE (7.5 ug/min)      ICU mortality, adverse events
           C = 42)                      C: 48.29 ± 12.53                                                                                   

  [@B14]   N = 526 (T = 260; C = 266)   T: 60.93 ± 15.86 C:61.09 ± 16.20   Terlipressin (20--160 ug/h with maximum\   NE (4--30 ug/min)    ICU mortality, adverse events
                                                                           infusion rate of 4 mg/day)                                      

  [@B17]   N = 39 (T = 19;\             T: 66 (28--84) C: 67(29--83)       Terlipressin (1 mg bolus)                  NE (84 ug/min)       ICU mortality, urinary output,\
           C = 20)                                                                                                                         total bilirubin, ALT, AST

  [@B18]   N = 30 (T = 15;\             T: 67 (60--71) C: 64 (59--72)      Terlipressin (1.3 ug/kg/h)                 NE (15 ug/min)       ICU mortality, MAP, HR, OI,\
           C = 15)                                                                                                                         Urinary output, Scr, total bilirubin, ALT, AST
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Quality Assessment {#s3_2}
------------------

Of the included studies, four of the six (66.7%) studies ([@B17]; [@B18]; [@B45]; [@B14]) obtained high scores (\>3) assessed by the modified Jadad scale. Only one study ([@B14]) reported allocation concealment. Two of the six studies ([@B5]; [@B16]) didn't report blinding method. The details of the quality assessment could be seen in [**Supplementary Table S1**](#SM9){ref-type="supplementary-material"}.

Primary Outcome {#s3_3}
---------------

The primary outcome of this study is 28-day mortality. Six studies reported 28-day mortality and the result showed that there was no difference between TP group and NE group (RR = 0.99, 95% CI = \[0.85,1.15\], P = 0.849) ([**Figure 2**](#f2){ref-type="fig"}).

![Forest plot of 28--day mortality.](fphar-10-01492-g002){#f2}

Secondary Outcomes {#s3_4}
------------------

The secondary outcomes included AE, MAP, HR, urinary output, Scr, OI, and total bilirubin. For the outcome of AE, there was no difference between the two groups (RR = 2.54, 95% CI = \[0.58, 11.08\], P = 0.214) ([**Figure 3**](#f3){ref-type="fig"}). In addition, for subgroup analysis, there was no difference in the adverse events of life-threatening arrhythmia (RR = 0.92, 95% CI = \[0.39,2.14\], P = 0.841) and peripheral cyanosis (RR = 8.98, 95% CI = \[0.59,137.83\], P = 0.115) between the two groups.

![Forest plot of AE.](fphar-10-01492-g003){#f3}

Two studies ([@B18]; Liu et al., 2017) reported the data of MAP; the result showed that there was no difference between the two groups (SMD = -0.10, 95% CI = \[-0.35,0.14\], P = 0.405) ([**Figure 4**](#f4){ref-type="fig"}). For subgroup analysis, there was no difference in 12 h (SMD = 0.27, 95% CI = \[-0.15,0.70\], P = 0.21), 24 h (SMD = -0.27, 95% CI = \[-0.69,0.16\], P = 0.216), and 48 h (SMD = -0.32, 95% CI = \[-0.74,0.11\], P = 0.144) between the two groups.

![Forest plot of MAP.](fphar-10-01492-g004){#f4}

For the outcome of the HR, the result showed that the TP group could decrease HR compared with the NE group (SMD = -0.59, 95% CI = \[-0.84,-0.34\], P = 0.000) ([**Figure 5**](#f5){ref-type="fig"}). For subgroup analysis, there was no difference at 12 h (SMD = -0.31, 95% CI = \[-0.73,0.11\], P = 0.151). However, the TP group could decrease HR at 24 h (SMD = -0.54, 95% CI = \[-0.97,-0.11\], P = 0.014) and 48 h (SMD = -0.95, 95% CI = \[-1.40,-0.51\], P = 0.000).

![Forest plot of HR.](fphar-10-01492-g005){#f5}

Two studies ([@B18]; Liu et al., 2017) reported the data of OI; the result showed that there was no difference between the two groups (SMD = 0.00, 95% CI = \[-0.24,0.25\], P = 0.97) ([**Supplemental Figure S2**](#SM2){ref-type="supplementary-material"}). For subgroup analysis, there was no difference in 12 h (SMD = -0.04, 95% CI = \[-0.47,0.38\], P = 0.841), 24 h (SMD = 0.03, 95% CI = \[-0.39,0.45\], P = 0.882), and 48 h (SMD = 0.03, 95% CI = \[-0.40,0.45\], P = 0.907) between the two groups.

For outcome of urinary output, the result showed that there was no difference between the two groups (SMD = 0.14, 95% CI = \[-0.12,0.39\], P = 0.304) ([**Supplemental Figure S3**](#SM3){ref-type="supplementary-material"}). For subgroup analysis, there was no difference in 4 h (SMD = 0.02, 95% CI = \[-1.14,1.18\], P = 0.977), 12 h (SMD = 0.18, 95% CI = \[-0.24,0.61\], P = 0.394), 24 h (SMD = -0.02, 95% CI = \[-0.44,0.41\], P = 0.937), and 48 h (SMD = 0.21, 95% CI = \[-0.58,0.99\], P = 0.609) between the two groups.

Two studies ([@B18]; Liu et al., 2017) reported the data of Scr; the result showed that there was no difference between the two groups (SMD = 0.11, 95% CI = \[-0.19,0.41\], P = 0.481) ([**Supplemental Figure S4**](#SM4){ref-type="supplementary-material"}). For subgroup analysis, there was no difference in 24 h (SMD = 0.23, 95% CI = \[-0.19,0.65\], P = 0.286) and 48 h (SMD = -0.02, 95% CI = \[-0.44,0.41\], P = 0.944) between the two groups.

For outcome of total bilirubin, the result showed that there was no difference between the two groups (SMD = -0.59, 95% CI = \[-1.25,0.08\], P = 0.084) ([**Supplemental Figure S5**](#SM5){ref-type="supplementary-material"}). For subgroup analysis, there was no difference in 12 h (SMD = -0.68, 95% CI = \[-1.94,0.58\], P = 0.288) and 24 h (SMD = -0.52, 95% CI = \[-1.59,0.54\], P = 0.339) between the two groups.

For outcome of ALT, the result showed that there was no difference between the two groups (SMD = -0.15, 95% CI = \[-0.50,0.19\], P = 0.383) ([**Supplemental Figure S6**](#SM6){ref-type="supplementary-material"}). For subgroup analysis, there was no difference in 12 h (SMD = -0.10, 95% CI = \[-0.81,0.62\], P = 0.789) and 24 h (SMD = -0.23, 95% CI = \[-0.71,0.24\], P = 0.333) between the two groups.

Two studies ([@B17]; [@B18]) reported the data of AST; the result showed that there was no difference between the two groups (SMD = -0.08, 95% CI = \[-0.44,0.28\], P = 0.657) ([**Supplemental Figure S7**](#SM7){ref-type="supplementary-material"}). For subgroup analysis, there was no difference in 12 h (SMD = -0.05, 95% CI = \[-0.77,0.68\], P = 0.901) and 24 h (SMD = -0.14, 95% CI = \[-0.63,0.36\], P = 0.586) between the two groups.

Discussion {#s4}
==========

Summary of Findings {#s4_1}
-------------------

To our knowledge, our study is the first meta-analysis to solely evaluate TP versus NE for septic shock patients. The results showed that there was no difference for 28-day mortality (RR = 0.99, 95% CI = \[0.85,1.15\], P = 0.849), AE (RR = 2.54, 95% CI = \[0.58,11.08\], P = 0.214), and MAP (SMD = -0.10, 95% CI = \[-0.35,0.14\], P = 0.405) between TP group and NE group. While TP could decrease HR at 24 and 48 h compared with NE ([**Table 2**](#T2){ref-type="table"}). Meanwhile, there was no difference for OI, urinary output, Scr, total bilirubin, ALT, and AST. That is to say, compared with NE, TP could decrease HR at 24 and 48 h without further liver and kidney injury, though TP showed no added survival benefit for septic shock.

###### 

Summary of meta-analysis.

  Outcomes          Subgroups   No. of studies   No. of participants   Effect size (95% CI)          I^2^    Z      P
  ----------------- ----------- ---------------- --------------------- ----------------------------- ------- ------ -------
  ICU mortality     NA          6                756                   RR, 0.99 \[0.85, 1.15\]       0       0.19   0.849
  Adverse events    a           2                546                   RR, 0.92 \[0.39, 2.14\]       0       0.20   0.841
                    b           2                546                   RR, 8.98 \[0.59, 137.83\]     83.3%   1.58   0.115
                    Overall     2                546                   RR, 2.54 \[0.58, 11.08\]      80.4%   1.24   0.214
  MAP               12 h        2                87                    SMD, 0.27 \[-0.15, 0.70\]     0       1.25   0.210
                    24 h        2                87                    SMD, -0.27 \[-0.69, 0.16\]    0       1.24   0.216
                    48 h        2                87                    SMD, -0.32 \[-0.74, 0.11\]    14.3%   1.46   0.144
                    Overall     2                87                    SMD, -0.10 \[-0.35, 0.14\]    32.3%   0.83   0.405
  HR                12 h        2                87                    SMD, -0.31 \[-0.73, 0.11\]    0       1.43   0.151
                    24 h        2                87                    SMD, -0.54 \[-0.97, -0.11\]   0       2.47   0.014
                    48 h        2                87                    SMD, -0.95 \[-1.40, -0.51\]   23.6%   4.18   0.000
                    Overall     2                87                    SMD, -0.59 \[-0.84, -0.34\]   11.8%   4.62   0.000
  OI                12 h        2                87                    SMD, -0.04 \[-0.47,0.38\]     18.8%   0.2    0.841
                    24 h        2                87                    SMD, 0.03 \[-0.39,0.45\]      0       0.15   0.882
                    48 h        2                87                    SMD, 0.03 \[-0.40,0.45\]      44.8%   0.12   0.907
                    Overall     2                87                    SMD, 0.00 \[-0.24,0.25\]      0       0.04   0.970
  Urinary output    4 h         2                59                    SMD, 0.02 \[-1.14,1.18\]      77.5%   0.03   0.977
                    12 h        2                87                    SMD, 0.18 \[-0.24,0.61\]      0       0.85   0.394
                    24 h        2                87                    SMD, -0.02 \[-0.44,0.41\]     0       0.08   0.937
                    48 h        2                87                    SMD, 0.21 \[-0.58,0.99\]      68.1%   0.51   0.609
                    Overall     4                146                   SMD, 0.14 \[-0.12,0.39\]      24.4%   1.03   0.304
  Scr               24 h        2                87                    SMD, 0.23 \[-0.19,0.65\]      0       1.07   0.286
                    48 h        2                87                    SMD, -0.02 \[-0.44,0.41\]     0       0.07   0.944
                    Overall     2                87                    SMD, 0.11 \[-0.19,0.41\]      0       0.70   0.481
  Total bilirubin   12 h        2                59                    SMD, -0.68 \[-1.94,0.58\]     83.7%   1.08   0.288
                    24 h        2                59                    SMD, -0.52 \[-1.59,0.54\]     78.3%   0.93   0.339
                    Overall     2                59                    SMD, -0.59 \[-1.25,0.08\]     72.4%   2.17   0.084
  ALT               12 h        2                59                    SMD, -0.10 \[-0.81,0.62\]     54.9%   0.33   0.789
                    24 h        2                59                    SMD, -0.23 \[-0.71,0.24\]     0       0.97   0.333
                    Overall     2                59                    SMD, -0.15 \[-0.50,0.19\]     6.1%    0.89   0.383
  AST               12 h        2                59                    SMD, -0.05 \[-0.77,0.68\]     55.9%   0.09   0.901
                    24 h        2                59                    SMD, -0.14 \[-0.63,0.36\]     7.4%    0.67   0.586
                    Overall     2                59                    SMD, -0.08 \[-0.44,0.28\]     13.4%   0.59   0.657

MAP, mean arterial pressure; HR, heart rate; NA, not available; a, Life-threatening arrhythmia; b, Peripheral cyanosis; OI, Oxygenation index; Scr, Serum creatinine; ALT, Alanine aminotransferase; AST, Aspartate transaminase; CI, confidence interval; RR, relative risks; WMD, weighted mean difference.

The Significance of This Study {#s4_2}
------------------------------

For decades ago, the application of NE and dopamine in septic shock has been controversial, and there were numerous studies and reviews to evaluate the efficacy and safety of these agents for septic shock ([@B22]; [@B20]; [@B19]; [@B21]). Based on this evidence, the guideline made a specific recommendation that NE should be used as a first-line drug for septic shock and dopamine is not recommended ([@B3]). However, we cannot ignore the clinical side effects of catecholamine resistance ([@B23]) and NE, such as severe malignant arrhythmias ([@B24]). Hence, seeking for alternative vasoactive drugs (especially for TP) has become the focus of septic shock treatment and research.

Recently, accumulating evidence suggested that TP has satisfactory effect to stabilize cardiocirculatory functions both in experimental and clinical sepsis ([@B6]). More importantly, TP could be used in patients with catecholamine-refractory septic shock who are resistant to catecholamines ([@B25]; [@B23]). Thus, TP seems to be an effective rescue strategy for patients who suffered from catecholamine-resistant septic shock ([@B26]). However, TP may be associated with unfavorable effects, such as impairment in cardiac index ([@B5]), ischemic skin lesions ([@B27]), and systemic oxygen delivery ([@B28]).

The Pharmacological Mechanism of TP {#s4_3}
-----------------------------------

Previous study investigated that activation of the V1 receptor results in vasoconstriction and arterial blood pressure ascent ([@B29]). However, arginine-vasopressin (AVP) has no selectivity for the V1 receptor and may produce side effects due to activation of the other receptors ([@B30]; [@B31]). TP has a much stronger selectivity to the V1 receptor than to other receptors. The chemical structure of TP is shown in [**Supplemental Figure S8**](#SM8){ref-type="supplementary-material"}.

Strengths and Limitations {#s4_4}
-------------------------

Our study is the first to directly compare TP with NE for septic shock, and a number of endpoints including ICU mortality, adverse events, heart rate, and mean arterial pressure were evaluated. Meanwhile, subgroups were conducted based on the different types of adverse events (AEs) or different time (MAP and HR). However, there were some limitations. First is due to the small sample size that limited the precision of the overall review. Second, we didn't conduct a subgroup meta-analysis based on the different timing of TP usage, since there were only some studies performed on animals ([@B33]; [@B32]) and case series ([@B35]; [@B34]).

The Significance of This Study for Future Clinical Practice and Research {#s4_5}
------------------------------------------------------------------------

Morelli et al. ([@B34]) conducted a case series; the results showed that skin necrosis occurred in patients treated with NE as first-line vasopressor and a delayed TP infusion. However, the patients treated with TP as first-line vasopressor survived and showed no signs of TP-related AEs. Taken together, with results from experimental studies ([@B33]; [@B36]) and previous clinical case reports ([@B37]; [@B35]), early low-dose infusion of TP may potentially be superior to a later resort strategy in septic shock. Recently, [@B38] reported that low dose of TP continuous infusion combined with NE has synergistic effect in septic shock patients. Taken together with the results from our meta-analysis, low dose of TP may be recommended as the first-line vasopressor for refractory hypotension. Thus, further studies are needed to evaluate the efficacy and safety of low dose of TP for refractory hypotension after septic shock.

Conclusions {#s5}
===========

Current results suggest that TP showed no added survival benefit for septic shock when compared with NE. While TP could decrease heart rate in the late phase of septic shock compared with NE without further liver and kidney injury.
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